Indications
Xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19.
Composition
- Active substance
- sotrovimab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xevudy
- Active substance
- sotrovimab
- ATC code
- J06BD05
- Therapeutic area
- COVID-19 virus infection
- Marketing authorisation holder
- GlaxoSmithKline Trading Services Limited